Potential cost savings of erythropoietin administration in end-stage renal disease

In a Department of Veterans Affairs randomized controlled trial, a lower dose of recombinant human erythropoietin (epoetin) was shown to attain target hematocrit levels when administered subcutaneously compared with intravenously. Since epoetin is expensive, optimizing the therapeutic effect of epoe...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The American journal of medicine 2002-02, Vol.112 (3), p.169-175
Hauptverfasser:	Hynes, Denise M, Stroupe, Kevin T, Greer, Joel W, Reda, Domenic J, Frankenfield, Diane L, Kaufman, James S, Henderson, William G, Owen, William F, Rocco, Michael V, Wish, Jay B, Kang, Jeffery, Feussner, John R
Format:	Artikel
Sprache:	eng
Schlagworte:	Anemia Biological and medical sciences Blood. Blood coagulation. Reticuloendothelial system Chronic renal disease Cost analysis Cost reduction Costs Costs and Cost Analysis Erythropoietin Erythropoietin - administration & dosage Erythropoietin - economics Erythropoietin - therapeutic use Female Hematocrit Hemodialysis Humans Injections, Intravenous Injections, Subcutaneous Kidney Failure, Chronic - drug therapy Kidney Failure, Chronic - etiology Male Medical sciences Medicare Medicare - economics Middle Aged Pharmacology. Drug treatments Randomized Controlled Trials as Topic Recombinant Proteins United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!